O TYM ODCINKU
In this episode of Cholesterol Conversations, Drs. Marc Bonaca, Pam Taub, and Heather Johnson discuss how multiagent therapy can improve the provision of care in the real world. Covered topics include new data from the 2023 ACC Scientific Sessions on the efficacy of novel agents and the role of combination therapy, as well as the importance of shared decision-making and keys to managing high-risk populations.
Język angielski
Stany Zjednoczone
W TYM ODCINKU
TRANSKRYPCJA 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
WYSZUKAJ MINIONE ODCINKI
Wyszukaj minione odcinki Cholesterol Conversations.
INNE ODCINKI W TYM PODCASCIE
Your patient's LDL-C is still above goal. What should you do next? Dr. Heather Johnson and Professor Viet Le put the 2026 dyslipidemia guidelines into clinical context and discuss how to use PREVENT-ASCVD, lipoprotein(a), and other risk markers to tailor treatment, set LDL goals, and determine when…
In this episode of Cholesterol Conversations, join Drs. Neha Pagidipati, Christie Ballantyne, and Gregory Piazza for a roundtable discussion that addresses recent guidance on ASCVD management, current gaps in ASCVD care, patient barriers to LDL-C lowering, and nonstatin therapies to consider for pa…
In this episode of Cholesterol Conversations, host Dr. Heather Johnson, Director of Preventive Cardiology for Women's Services at the Christine E. Lynn Women's Health & Wellness Institute of Baptist Health South Florida, sits down with Dr. Viet T. Le, Associate Professor of Research and Co-Dire…
Zastrzeżenie: Podcast i grafika osadzone na tej stronie pochodzą z Vasculearn Network, który jest własnością jego właściciela i nie jest powiązany ani wspierany przez Listen Notes, Inc.
EDYTUJ
Dziękujemy za pomoc w aktualizowaniu podcastowej bazy danych.
